A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Mavorixafor (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors X4 Pharmaceuticals
- 02 Jan 2019 Status changed from recruiting to completed.
- 18 Apr 2018 As of September 15, 2017, 13 patients have been enrolled, and 11 have completed the study, according to results presented at the 109th Annual Meeting of the American Association for Cancer Research.
- 18 Apr 2018 Results (n=13) assessing safety and tolerability of X4P-001 in combination with Keytruda (pembrolizumab) in patients with advanced melanoma, were presented at the 109th Annual Meeting of the American Association for Cancer Research.